Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2053 in primary hypercholesterolemia or mixed dyslipidemia
NCT07421284Phase 3Not yet recruiting
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 3 trial of SYH2053 in hypercholesterolemia, mixed dyslipidemia, sponsored by CSPC Zhongnuo Pharmaceutical. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
SYH2053
03
Conditions
hypercholesterolemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT07421284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07421284.